NewAmsterdam Pharma vs Roivant Sciences
NAMS and ROIV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NAMS and ROIV compare
Roivant Sciences grew revenue faster over the last twelve months (−67.6% versus −88.9% for NewAmsterdam Pharma).
Roivant Sciences keeps more of each dollar of sales as profit, with a net margin of −3535% compared with −3644% at NewAmsterdam Pharma.
Roivant Sciences scores higher on the StockData Score (7 against 6 for NewAmsterdam Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NAMS | ROIV |
|---|---|---|
| Size and price | ||
| Market cap | – | $26.7B |
| Share price | $20.06 | $36.91 |
| Change, 1 year | −44.0% | 96.7% |
| Change, 5 years | 104% | 377% |
| Beta (5Y) | 0.81 | 0.86 |
| Employees | 100 | 721 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 3540× |
| P/B | – | 6.3× |
| FCF yield | – | −3.1% |
| Growth | ||
| Revenue growth (TTM) | −88.9% | −67.6% (better) |
| Revenue growth, 5Y average | – | −19.1% |
| Profitability | ||
| Operating margin | −3432% (better) | −7915% |
| Net margin | −3644% | −3535% (better) |
| FCF margin | −2018% (better) | −10901% |
| Return on equity | −36.8% | −6.2% (better) |
| Return on invested capital | −1046% | −407% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 9.03 | 16.72 (better) |
| Altman Z-score | – | 41.99 |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | – | 78.1% |
| Held by insiders | 22.1% | 14.3% |
| Insider net buying, 12 months | −$61.8M (better) | −$870M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 6.3% |
Go deeper
- NAMS stock overview
- NAMS income statement
- NAMS valuation and score
- ROIV stock overview
- ROIV income statement
- ROIV valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.